CONTENT VALIDATION AND
DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art
education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or
apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of
each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance,
scientific objectivity of studies referenced and patient care recommendations.
The scientific staff and consultants for Research To Practice are involved in the development and review of content for
educational activities and report the following real or apparent conflicts of interest, either current or within the past 12
months, for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard
Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD,
Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-
Alibozek, PA-C, MPAS — salary: AstraZeneca Pharmaceuticals LP; shareholder of AstraZeneca Pharmaceuticals LP;
Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives
education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals
Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic
Health Inc, GPC Biotech, ImClone Systems, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the
content development of our educational activities.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that
have been resolved through a peer review process:
Dr Berlin — Clinical Director, GI Oncology; Associate Professor of Medicine, Vanderbilt-Ingram Cancer Center,
Nashville, Tennessee. Consulting Fees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company,
Genentech BioOncology, ImClone Systems, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis. Dr Ellis — Professor of Surgery and Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston,
Texas. Consulting Fees: Genentech BioOncology, ImClone Systems; Contracted Research: Amgen Inc, ImClone
Systems; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Genentech
BioOncology. Dr Fuchs — Associate Professor of Medicine, Dana-Farber Cancer Institute, Harvard University, Boston,
Massachusetts. Consulting Fees: Genentech BioOncology, Pfizer Inc, Sanofi-Aventis. Dr Goldberg — Professor and
Chief, Division of Hematology/Oncology; Associate Director, UNC/Lineberger Comprehensive Cancer Center, UNC
School of Medicine, Chapel Hill, North Carolina. Consulting Fees: Amgen Inc, AstraZeneca Pharmaceuticals LP,
Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Genentech BioOncology, ImClone Systems, Pfizer Inc,
Sanofi-Aventis. Dr Grothey — Senior Associate Consultant, Department of Medical Oncology, Mayo Clinic, Rochester,
Minnesota. Consulting Fees: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Roche Laboratories
Inc, Sanofi-Aventis. Dr Haller — Professor of Medicine, Abramson Cancer Center at the University of Pennsylvania,
Philadelphia, Pennsylvania. Consulting Fees and Contracted Research: Amgen Inc, Bristol-Myers Squibb Company,
Genentech BioOncology, Roche Laboratories Inc, Sanofi-Aventis, Taiho Pharmaceutical Co Ltd; Fees For Non-CME
Services Received Directly from Commercial Interest or Their Agents: Genentech BioOncology, Roche Laboratories
Inc, Sanofi-Aventis. Dr Hochster — Professor of Medicine and Clinical Pharmacology, NYU Cancer Institute, New York,
New York. Consulting Fees: Amgen Inc, Genentech BioOncology, Roche Laboratories Inc, Sanofi-Aventis; Fees for
Non-CME Services Received Directly from Commercial Interests or Their Agents: Genentech BioOncology, Sanofi-
Aventis. Dr Hurwitz — Associate Professor of Medicine, Division of Hematology/Oncology; Clinical Director, Phase I
Program; Co-leader, GI Oncology Program, Duke University Medical Center, Durham, North Carolina. Consulting Fees:
Bristol-Myers Squibb Company, Genentech BioOncology, Roche Laboratories Inc; Contracted Research: AstraZeneca
Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc, Roche
Laboratories Inc, Sanofi-Aventis, Sunesis Pharmaceuticals Inc; Fees for Non-CME Services Received Directly from
Commercial Interest or Their Agents: Genentech BioOncology. Dr Meropol — Director, Gastrointestinal Cancer
Program; Director, Gastrointestinal Tumor Risk Assessment Program, Divisions of Medical Science and Population
Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Consulting Fees: Amgen Inc, Genentech BioOncology,
Pfizer Inc; Contracted Research: Genentech BioOncology. Dr Tepper — Hector McLean Distinguished Professor of
Cancer Research, Department of Radiation Oncology, UNC/Lineberger Comprehensive Cancer Center, UNC School of
Medicine, Chapel Hill, North Carolina. No financial interests or affiliations to disclose. Dr Wolff — Associate Professor
of Medicine; Deputy Chairman for Clinical Affairs, Department of Gastrointestinal Medical Oncology, The University of
Texas MD Anderson Cancer Center, Houston, Texas. Contracted Research: Genentech BioOncology, Sanofi-Aventis. Dr Wolmark — Professor and Chairman, Department of Human Oncology, Allegheny General Hospital; Professor,
Drexel University College of Medicine; Chairman, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh,
Pennsylvania. No financial interests or affiliations to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by
the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled
indications. Please refer to the official prescribing information for each product for discussion of approved indications,
contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those
of the publisher or grantors.
